Bespoke immunotherapy: how close are we?

Neuro Oncol. 2019 Feb 19;21(3):289-290. doi: 10.1093/neuonc/noz017.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cancer Vaccines*
  • Double-Blind Method
  • Glioblastoma*
  • Humans
  • Immunotherapy
  • Vaccines, Subunit

Substances

  • Cancer Vaccines
  • Vaccines, Subunit